Grants
Major funds from public R&D Grants
Currently running
Project identification number: RRF-2.3.1-21-2022-00003
Project title: National Cardiovascular Laboratory
Project purpose briefly: Development of new preventive, diagnostic and therapeutic procedures
Project data:
Consortium leader: Semmelweis University
Consortium members: University of Szeged, 3DHISTECH Ltd., Neumann Medical Ltd., PHARMAHUNGARY 2000 Ltd.
Grant identification number: RRF-2.3.1-21-2022-00003
Total project cost: 5 670 176 720.-Ft
Amount of support: 96,12%
Consortium members and amount of support received:
| Consortium member | Support received |
Self contribution | Total project cost |
| Semmelweis University | 4 950 000 000 Ft | 0 Ft | 4 950 000 000 Ft |
| Neumann Medical Ltd. | 150 000 000 Ft | 37 500 000 Ft | 187 500 000 Ft |
| PHARMAHUNGARY 2000 Ltd. | 149 999 999 Ft | 32 676 721 Ft | 182 676 720 Ft |
| University of Szeged | 50 000 000 Ft | 0 Ft | 50 000 000 Ft |
| 3DHISTECH Ltd. | 150 000 000 Ft | 150 000 000 Ft | 300 000 000 Ft |
Planned project duration: March 1, 2022 – February 28, 2026
Short description of project: The National Cardiovascular Laboratory undertakes revolutionary research into the pathophysiological mechanisms involved in the development of aging-related cardiovascular diseases, with the aim of developing and implementing new, innovative preventive, diagnostic and therapeutic procedures based on the results of the research.
Pillars of professional implementation:
The national lab program is based on the following main translational research projects, product and service development professional pillars.
1. Clinical-epidemiological programs: During the program, we will test the implementation possibilities of the new procedures using an evidence-based indicator system in THE a cohort study (Semmelweis Study) carried out within Semmelweis University. The tests of the cardiovascular research program of the Program for Healthy Aging, which will be developed with the help of the program, are embedded in this study. The program will conduct research and development of innovative screening, diagnostic and therapeutic methods, services and products aimed at reducing the incidence and mortality of ischemic heart disease and heart failure. As part of its clinical-epidemiological programs, the National Cardiovascular Laboratory maps the potential mid- and long-term cardiovascular effects of the COVID-19 infection with multimodal clinical and detailed follow-up. We plan to close the BUDAPeST Upgrade CRT international clinical trial, based on the results of which new professional guidelines will be developed.
2. Innovative drug-biotechnological developments: The National Cardiovascular Laboratory will detect new drug attack points and reposition existing drugs within the framework of its innovative drug-biotechnological development program. The analysis of the gene and protein expression pattern of the patient’s heart muscle tissue will be done with the development and application of integrative, network theory and artificial intelligence based systems, as a result of which new drug targets will be identified and drug repositioning developments will be implemented. Important elements of the program: development of in vitro cardiovascular platforms, further development of microRNA-based pharmacotherapy solutions, cardio-oncology studies, marketing of software supporting RNA-based molecular bioinformatics drug development and drug safety developments.
3. Development of innovative medical and diagnostic devices and databases: As part of the National Cardiovascular Laboratory’s programs aimed at the development of innovative medical and diagnostic devices and databases, the identification and validation of extracellular vesicle-based diagnostic and therapeutic effect markers and measurement methods will take place. Further development of software used for „big data” network analysis and supporting structured retrieval is also an element of the program. A laboratory test suitable for determining biological age and the associated software will also be introduced.
Expected results and their impact: The research results of the National Cardiovascular Laboratory will make a decisive contribution to the development of evidence-based cardiovascular health promotion and disease prevention programs, helping to achieve the goal that the country’s population can live a healthy life even in old age. The interdisciplinary and translational nature of the program guarantees that it will successfully implement the development of evidence-based innovative disease prevention, screening, diagnostic and therapeutic procedures suitable for reducing the incidence and mortality of cardiovascular diseases. The results of the program contribute to the international market of innovative products and services with high economic added value, thereby helping the development of the domestic pharmaceutical biotechnology industry.
Commercial & Research Opportunity for Cysteinyl Leukotriene Signalling in Ocular & CNS Dysfunction, Cancer and Cardiovascular Disease
Name of beneficiary: Pharmahungary 2000 Ltd., a member of the Pharmahungary Group
Acronym: CRYSTAL3
Short description of project: The project is focusing on commercial and research opportunities of a relatively unexplored inflammation-related signalling pathway.
Central to this pathway are powerful molecules called cysteinyl leukotrienes (CysLTs) that are involved in the process of inflammation – the body’s response to fight injury or pathogens. CysLT signalling receptors are found widely in the body e.g. lungs, colorectum, heart, brain & eye.
Currently, drugs targeting CysLT receptors are prescribed to treat airway inflammation. Recently, CysLT signalling was implicated in regulating cells in cancer, cardiovascular disease and diseases involving the eye and central nervous system. The CRYSTAL3 consortium will determine how CysLT signalling links to these diseases, then explore potential targeted therapies and how any products and services co-developed can be commercialised.
Grant identification number: H2020-RISE2020/GA101007931
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101007931.
Title: Development of microRNA-based therapy for cardiovascular diseases and marketization of related complex R&D service solutions
Name of beneficiary: Pharmahungary 2000 Ltd., a member of the Pharmahungary Group
Short description of the project: The development of non-coding RNAs (such as microRNAs) as molecules with diagnostic and therapeutic value has come to the forefront of the pharmaceutical industry in recent years for the precision diagnosis and treatment of many diseases. In 2013, Pharmahungary 2000 Ltd., a member of the Pharmahungary Group was the first in the world to patent 3 families of microRNA molecules for protection against acute myocardial infarction (termed ProtectomiRs, see www.protectomir.com). Furthermore, Pharmahungary developed a software for the network analysis of microRNA expression pattern (see www.mirnatarget.com) as well as a platform for the isolation of microvesicles for the delivery of microRNAs (see www.vezics.com).
During the grant Pharmahungary will expand and significantly increase the market value of its intellectual property portfolio by:
1. Vezics: creating an extracellular vesicle-based therapeutic system carrying ProtectomiR microRNA molecules that protect the heart
2. ProtectomiR: further developing patent protected and novel ProtectomiRs including pharmacokinetic and efficacy studies
3. miRNAtarget: studying the efficiency of microRNA transfer via investigating the effect of microRNA on the target messenger RNA as well as further developing our bioinformatics platform
Planned project duration: September 1, 2021 – August 31, 2024
Total financial support: 107.100.000 Ft (approx. 295 000 EUR)
Grant identification number: 2020-1.1.5-GYORSÍTÓSÁV-2021-00011
Closed grants
A diagnostic test to improve surveillance and care of COVID-19 patients
Name of beneficiary: Pharmahungary 2000 Ltd., a member of the Pharmahungary Group
Acronym: COVIRNA
Short description of project: COVIRNA is a patient-centred Innovation Action aiming to generate a diagnostic tool to identify COVID-19 patients at risk of developing fatal cardiovascular complications, ultimately leading to their improved surveillance and care. In particular, the project will complete and deploy a prognostic system based on cardiovascular biomarkers of COVID-19 clinical outcomes, combined with a predictive model built on digital tools and artificial intelligence analytics. Building on the network developed within the EU-CardioRNA (“Catalyzing transcriptomics research in cardiovascular disease”) COST Action, a consortium of 15 academic and innovative SME partners polled their expertise and resources (notably by providing access to various European COVID-19 clinical cohorts) to build a multidisciplinary and multicentre study with the common aim to improve individualised surveillance, care and follow-up of COVID-19 patients in the context of the current pandemic.
Awarded under the topic SC1-PHE-CORONAVIRUS-2B (Medical technologies, Digital tools and Artificial Intelligence (AI) analytics to improve surveillance and care at high Technology Readiness Levels), the COVIRNA project started in November 2020 and will last 24 months. For more details see www.covirna.eu.
Grant identification number: No. 101016072
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101016072.
Catalyzing transcriptomics research in cardiovascular disease
Name of beneficiary: Pharmahungary 2000 Kft., member of Pharmahungary Group
Acronym: CardioRNA
Short description of project: Pharmahungary Group joins COST Action titled CardioRNA – “Catalyzing transcriptomics research in cardiovascular disease”. The COST Action was proposed by Cardiolink Board Members and co-proposed by other 19 Cardiolinc members and partners.
The aim of the CardioRNA COST Action is to accelerate the understanding of transcriptomics in cardiovascular disease and further the translation of experimental data into practical applications for diagnostics and therapies to improve personalized medicine.
The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. CardioRNA aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic.
Grant identification number: CA17129
Realising the therapeutic potential of novel cardioprotective therapies
Name of beneficiary: Pharmahungary 2000 Kft., member of Pharmahungary Group
Acronym: EU-Cardioprotection
Short description of project: The main challenge is to improve the translation of novel cardioprotective therapies shown to be effective in the pre-clinical setting into the clinical arena for patient benefit. This COST Action (termed EU-CARDIOPROTECTION) aims to address this challenge by setting up a Europe-wide network of research centers tasked with: (1) the discovery of new therapeutic targets and innovative strategies for cardioprotection; (2) testing the effects of combination therapy to target multiple signaling pathways both within and outside the cardiomyocyte; 3) investigating the effects of confounders (co-morbidities and co-medications) on cardioprotection; (4) multi-center pre-clinical and clinical testing of novel cardioprotective therapies.
Grant identification number: COST CA16225
National Heart Program: Research and innovation in diagnostics and therapy of ischemic heart disease and heart failure
Short title: National Heart Program
Name of beneficiary: Pharmahungary 2000 Kft., member of Pharmahungary Group
Total financial support for consortium: 3.299.426.997 HUF (approx. 10.686.405 EUR)
Rate of support: 90,50%
Background: In Hungary ischemic heart disease and heart failure are the leading cause of death. The objective of the grant is to develop therapies that reduce death by cardiovascular diseases.
Implementation: Cardiology research group of Semmelweis University (including clinical, pharmacology, bio-physics, inflammation-immunology, and bioinformatics researchers) and 4 R&D companies including Pharmahungary Group will implement the program. The consortium will develop innovative diagnostic and therapeutic approaches as well as novel products and services via interdisciplinary, integrated translational (from basic research to epidemiology) R&D projects.
Outcomes: Development of innovative R&D platforms based on in vitro and in vivo models, development of new diagnostic imaging equipment and bioinformatics solutions, identification of cost effective diagnostic and therapeutic molecular targets, screening of hidden cardiotoxicity of therapies, personalized risk assessment by multiomics analysis, novel cardiovascular therapies by medical devices, and medical guidelines.
Planned project duration: December 1, 2016 – November 30, 2019
Grant identification number: NVKP_16-1-2016-0017
For more information on the members of the consortium, see website.
Synthesis, chemoinformatic development, optimization and preclinical testing of matrix metalloproteinase-2 inhibitors for cardioprotection.
Awarded by National Research, Development, and Innovation Office of Hungary and Department of Science & Technology of India
Name of beneficiary: Pharmahungary 2000 Kft., member of Pharmahungary Group
Project title: Synthesis, chemoinformatic development, optimization and preclinical testing of matrix metalloproteinase-2 inhibitors for cardioprotection
Total financial support: 164.000 EUR
Short description of project: This project is aimed to develop effective matrix metalloproteinase-2 inhibitors to treat myocardial infarction one of the leading cause of death and morbidity in India and Hungary. The project will be performed in collaboration of three research teams including a small-medium R&D enterprise (SME) in Hungary (see www.pharmahungary.com). It is planned to design, synthesize, study of novel substituted methylamino azole derivatives as Matrix Metalloproteinase (MMPs) inhibitors.
Planned project duration: 2016-2019, project end-date: December 31, 2019
Grant identification number: TÉT_15_IN-1-2016-0068
Protect title: Maintenance and validation of the European regional patent application for the invention titled „Use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions”.
Name of beneficiary: Pharmahungary 2000 Kft., member of Pharmahungary Group
Total financial support: 2.337.200 HUF
Rate of support: 100%
Short description of project: The aim of this grant was to maintain and validate the European regional patent application for the invention titled „Use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions”. For more information see: www.biglycan.com.
Project end date: December 5, 2017
Grant identification number: GINOP-2.1.3-15-2015-00024
SME Instrument Phase I winner
Project title: Novel biomarker diagnostic system for the assessment of the prognosis of acute myocardial ischemia/reperfusion injury and infarction and the effectiveness of the treatment
Short title: Infarnosys™
Short description of project: Novel biomarker diagnostic method and assay kit that will help clinical doctors in an early diagnosis of cardiac events and to evaluate the severity of injury caused by an infarction, and more importantly, the effectiveness of its treatment. Therefore, the technology will also contribute to a better planning of treatments.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 698297.
Purchase and installation of a small-animal ultrasonic imaging system, Baross Gabor program, National Office for Research and Technology (INPHARMA project, awarded for 2010)
Development of Innovative technology platform for the preclinical screening of metabolic diseases. Baross Gabor program, National Office for Research and Technology (METABBET project, awarded for the period of 2009-2011)
Technology transfer support of the cardiovascular R&D projects of Pharmahungary. Baross Gabor program, National Office for Research and Technology, awarded for 2009.
Development of “dietary foods for special medical purposes” for patients suffering from diabetes, atherosclerosis and coronary heart disease. National Technology Platform (MED-FOOD project, awarded for the period of 2008-2012)
Platform of mouse and human embryonic stem cell-derived cardiomyocyte test systems for drug development. Jedlik Anyos Grant (ES2HEART project, awarded for the period of 2008-2010)
Development of drug candidates based on genomics and chemoinformatics against myocardial infarction: inhibitors of matrix metalloproteinases. Jedlik Anyos Grant (NKFP_06_A1_MMP_2006 project, awarded for the period of 2007-2010). For further information: www.mmpharma.com.
Modulation of peroxynitrite-induced myocardial damage by pharmacological and gene therapies, and development of clinical applications of peroxynitrite markers. GVOP Grant (GVOP-331-2004-04-0095_30, awarded for the period of 2005-2007)